PMID: 9630803Jun 19, 1998Paper

Angiogenesis inhibitors in advanced cancer. Many current clinical trials show promising results

Läkartidningen
R Christofferson

Abstract

Tumour growth and metastasis are dependent on angiogenesis, the formation of new blood vessels. In experimental models, tumour regression can be induced by the administration of specific angiostatic agents. The inhibition of angiogenesis represents a new approach in cancer therapy. Specific inhibition of angiogenesis is not characterised by the typical dose-limiting toxicity of chemotherapy. By targeting the untransformed and genetically stable vascular endothelium, drug delivery is no problem, and angiostatic therapy is not associated with the development of drug resistance. However, the treatment has to be continued for months or years, and some angiostatic agents are known to interfere with fertility. Approximately thirty angiostatic agents are undergoing clinical trials, and another fifty agents preclinical testing. Since the clinical trials are performed on patients with advanced tumours intractable to conventional therapy, and as the test drugs are first generation angiostatic agents, their effect is measured in terms of delay in tumour progression or reduction in values for surrogate endpoints such as tumour markers. In this article, based on reports presented at a recent international conference on angiogenesis antagoni...Continue Reading

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Related Papers

Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
Esther A KleibeukerVictor L Thijssen
Frontiers in Bioscience : a Journal and Virtual Library
Zoltán SzekaneczAlisa E Koch
© 2022 Meta ULC. All rights reserved